Evidence map›Paper›PMID 30783853›Full record

Trial reportAnnals of surgical oncology2019

Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast.

Philip M Spanheimer, Melissa P Murray, Emily C Zabor, Michelle Stempel, Monica Morrow, Kimberly J Van Zee, Andrea V Barrio

Abstract readClinical Trial
In one paragraph

Trial report in Annals of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Clinical case giant malignant phyllodes tumor of the breast.Journal of surgical case reports · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Prognostic factors of breast phyllodes tumors.Histology and histopathology · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Philip M SpanheimerBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Melissa P MurrayBreast Pathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Emily C ZaborBiostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michelle StempelBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Monica MorrowBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kimberly J Van ZeeBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrea V BarrioBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. barrioa@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748NIH/NCI Cancer Center Support Grant P30 CA008748
6 · The paper itself

Abstract

backgroundMalignant/borderline phyllodes tumors (PTs) are rare, and little is known about their long-term prognosis. This study sought to evaluate recurrence rates and identify factors associated with local and distant failure.

methodsFrom 1957 to 2017, we identified 124 patients with 125 PTs (86 malignant and 39 borderline). Recurrence rates and survival were assessed using the Kaplan-Meier method, and correlated with clinicopathologic factors using the log-rank test.

resultsThe median age of the patients was 44 years, and the median tumor size was 5 cm. Breast-conserving surgery was performed for 57% of the patients. At a median follow-up of 7.1 years, 14 patients experienced a locoregional recurrence (LRR), with a 10-year cumulative LRR incidence of 12%. On univariable analysis, age younger than 40 years (p = 0.02) and close/positive margins (p = 0.001) were associated with increased risk of LRR. Seven patients developed distant disease, all occurring in malignant PTs. The 10-year distant recurrence-free survival was 94%. Uniformly poor pathologic features consisting of marked stromal cellularity, stromal overgrowth, infiltrative borders, and 10 or more mitoses per 10 high-power fields (hpf) were identified in 25 PTs (20%), and all distant recurrences occurred in this group. For the patients who did not have uniformly poor features, the 10-year disease-specific survival was 100%, and the overall survival was 94% compared with 66% and 57%, respectively, among those with poor features.

conclusionMalignant/borderline PTs without uniformly poor histologic features have an excellent prognosis after surgical resection, with a 10-year disease-specific survival of 100%. The presence of uniformly poor pathologic features predicts a poor prognosis. Efforts should be directed toward new treatment approaches for these tumors.

Indexed as

Margins of ExcisionAdolescentAdultAgedAged, 80 and overBreast NeoplasmsCohort StudiesFemaleFollow-Up StudiesHumansMastectomyMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalPhyllodes TumorPrognosis

Identifiers

PMID30783853
PMCPMC6545258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.